By NZ Gastro Office | Posted: Thursday April 6, 2023
We are canvassing opinion from members as to what information and what format they may find more useful in a guide.
As part of the NZSG's ongoing work it has been proposed that the NZSG IBD Medication Group produce some guidance for the use of biologics in inflammatory bowel disease now that new agents (vedolizumab and ustekinumab) have been funded.
Prior to undertaking this we are canvassing opinion from members as to what information and what format they may find more useful. Our proposal is for a focused guideline to help with decision-making within the New Zealand prescribing landscape. We are hopeful that some adjustments to special authority criteria may be leveraged off such a guideline. Pharmac have indicated they would take this into consideration.
Please take part by completing this survey